Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report

Am J Clin Oncol. 1999 Oct;22(5):466-70. doi: 10.1097/00000421-199910000-00009.

Abstract

The chemotherapeutic agent 5-fluorouracil (5-FU) is a widely accepted part of many cancer treatment protocols. Its cardiotoxic potential is known, but considered uncommon and usually not life threatening, although some cases of severe cardiotoxicity related to 5-FU have been reported. The pathogenesis of cardiotoxicity caused by 5-FU is not clear. We report a case of sudden onset of severe cardiac failure, without ischemic symptoms or signs, during 5-FU treatment with serious consequences, in a previously healthy 23-year-old patient with squamous cell carcinoma of the tongue. Endomyocardial biopsy showed proliferation of the sarcoplasmic reticulum with marked vacuolization, similar to that found with doxorubicin cardiotoxicity. Because 5-FU cardiotoxicity is unpredictable and can have potentially fatal consequences, it requires, in our opinion, further clarification. With this well-documented case, including an endomyocardial biopsy, we hope to encourage additional efforts to investigate the pathophysiologic mechanisms of 5-FU cardiotoxicity.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Antimetabolites, Antineoplastic / adverse effects*
  • Carcinoma / drug therapy*
  • Fluorouracil / adverse effects*
  • Heart Diseases / chemically induced
  • Humans
  • Male
  • Tongue Neoplasms / drug therapy*
  • Ventricular Dysfunction, Left / chemically induced*
  • Ventricular Dysfunction, Left / pathology

Substances

  • Antimetabolites, Antineoplastic
  • Fluorouracil